FrancophonIA/ELRC3.0 huggingface dataset:
English: Aprepitant (125 mg/80 mg) is a substrate, a moderate inhibitor, and an inducer of CYP3A4.
Maltese: Aprepitant (125 mg/80 mg) huwa substrat, inibitur moderat, u jinduċi CYP3A4.
English: EMEND contains sucrose and lactose
Maltese: EMEND fih sucrose u lactose
English: Percentage point difference (%) and 95 % C.I.
Maltese: Id-differenza f'punt perċentwali u 95 % C.I. #
English: The antiemetic activity of aprepitant was evaluated during the 0 to 48 hour period following the end of surgery.
Maltese: L-attività anti-emetika ta' aprepitant ġiet evalwata waqt il-perijodu ta' 0 sa 48 siegħa wara tmiem il-kirurġija.
English: Aprepitant Regimen (N=520) Standard Therapy (N=523)
Maltese: Kors ta' Aprepitant (N=520) Terapija standard (N=523)
English: Elderly (≥ 65 years)
Maltese: Anzjani (≥65 sena)
English: 1 hard capsule
Maltese: 1 kapsula iebsa
English: Percent of Patients
Maltese: Percentwal ta' Pazjenti
English: Aprepitant is a selective high-affinity antagonist at human substance P neurokinin 1 (NK1) receptors.
Maltese: Aprepitant huwa antagonist selettiv b'affinità kbira għar-riċetturi tas-sustanza umana P neurokinin 1 (NK1).
English: EMEND 40 mg is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.
Maltese: EMEND 40 mg hu indikat għall-prevenzjoni ta' nawseja u rimettar wara operazzjoni (PONV) fl-adulti.
English: Complete response to the aprepitant regimen and standard therapy, respectively, was reached in 209/324 (65 %) and 161/320 (50 %) in women and 83/101 (82 %) and 68/87 (78 %) of men.
Maltese: Rispons sħiħ għall-iskeda ta' kura b'aprepitant u t-terapija standard, rispettivament, inkiseb f'209/324 (65 %) u 161/320 (50 %) fin-nisa u f'83/101 (82 %) u 68/87 (78 %) tal-irġiel.
English: EU/1/03/262/001 EU/1/03/262/002 EU/1/03/262/003 EU/1/03/262/004 EU/1/03/262/005 EU/1/03/262/006
Maltese: EU/1/03/262/001 EU/1/03/262/002 EU/1/03/262/003 EU/1/03/262/004
English: Day 1
Maltese: Figura 1
English: PRIMARY ENDPOINT Complete response
Maltese: SKOP FINALI PRIMARJU
English: 3-day regimen of aprepitant in adults
Maltese: Kors ta' 3 ijiem ta' aprepitant fl-adulti
English: The Cmax was 10 % higher on Day 1 and 24 % higher on Day 5 in elderly relative to younger adults.
Maltese: Is-Cmax kien 10 % ogħla f'Jum 1 u 24 % ogħla f'Jum 5 fl-anzjani meta mqabbel ma' adulti iżgħar fl-età.
English: Infection and infestations candidiasis, staphylococcal infection rare
Maltese: Infezzjonijiet u infestazzjonijiet kandidajażi, infezzjoni ta' staphylococcus rari
English: Patients were randomised to receive 40 mg aprepitant, 125 mg aprepitant, or 4 mg ondansetron.
Maltese: Il-pazjenti ġew maqsumin sabiex b'mod każwali jingħataw 40 mg aprepitant, 125 mg aprepitant, jew 4 mg ondansetron.
English: Standard therapy (N= 406)
Maltese: (N= 406)
English: The safety and exploratory efficacy of aprepitant were evaluated in a Phase I clinical study (n=50) using a 40 mg powder for oral suspension.
Maltese: Is-sigurtà u l-effikaċja esploratorja ta' aprepitant ġew ivvalutati fi studju kliniku ta' Fażi I (n=50) blużu ta' 40 mg trab għal suspensjoni orali.
English: Fosaprepitant placebo, aprepitant placebo, and dexamethasone placebo (in the evenings on Days 3 and 4) were used to maintain blinding (see section 4.2).
Maltese: Il-plaċebo ta' fosaprepitant, il-plaċebo ta' aprepitant, u l-plaċebo ta' dexamethasone (filgħaxijiet tal-Jiem 3 u 4) intużaw biex l-istudju jibqa' blind (ara sezzjoni 4.2).
English: Aprepitant regimen (N= 425)
Maltese: Aprepitant (N= 425)
English: 1 hard capsule 5 x 1 hard capsule
Maltese: 5 x 1 kapsula iebsa
English: EMEND contains sucrose
Maltese: EMEND fih sucrose
English: Adverse reactions were reported in approximately 4 % of adults treated with 40 mg aprepitant compared with approximately 6 % of patients treated with 4 mg ondansetron intravenously.
Maltese: Reazzjonijiet avversi ġew irraportati f'madwar 4 % tal-adulti trattati b'40 mg aprepitant meta mqabbla ma' madwar 6 % tal-pazjenti li kienu qed jiġu kkurati b'4 mg ondansetron fil-vini.
English: Date of first authorisation: 11 November 2003 Date of latest renewal: 22 September 2008
Maltese: Data tal-aħħar tiġdid: 22 ta' Settembru 2008
English: EMEND powder for oral suspension is given as part of combination therapy (see section 4.2).
Maltese: EMEND trab għal suspensjoni orali jingħata bħala parti minn terapija kombinata (ara sezzjoni 4.2).
English: The safety profile of aprepitant was evaluated in approximately 6,500 adults in more than 50 studies and 184 children and adolescents in 2 pivotal paediatric clinical trials.
Maltese: Il-profil tas-sigurtà ta' aprepitant ġie evalwat f'madwar 6,500 adult f'aktar minn 50 studju u 184 tfal u adolexxenti f'2 provi kliniċi pivitali fit-tfal.
English: In vitro studies using human liver microsomes indicate that aprepitant is metabolised primarily by CYP3A4 and potentially with minor contribution by CYP1A2 and CYP2C19.
Maltese: Studji in vitro bl-użu ta' mikrosomi tal-fwied umani ndikaw li aprepitant huwa metabolizzat primarjament permezz ta' CYP3A4 u potenzjalment b'kontribuzzjoni minuri permezz ta' CYP1A2 u CYP2C19.
English: EMEND powder for oral suspension contains sucrose and lactose.
Maltese: EMEND trab għal suspensjoni orali fih sucrose u lactose.
English: Twelve metabolites of aprepitant have been identified in human plasma.
Maltese: Tnax-il metabolit ta' aprepitant ġew identifikati fil-plażma umana.
English: In controlled clinical studies in adults receiving general anaesthesia, 564 patients were administered 40 mg aprepitant orally and 538 patients were administered 4 mg ondansetron intravenously.
Maltese: Fi studji kliniċi kkontrollati, li saru f'adulti li kienu qed jirċievu anestesija ġenerali, 564 pazjent ingħataw 40 mg aprepitant mill-ħalq u 538 pazjent ingħataw 4 mg ondansetron fil-vini.
English: EMEND 125 mg/80 mg is given as part of combination therapy (see section 4.2).
Maltese: EMEND 125 mg/80 mg jingħata bħala parti minn terapija ta' kombinazzjoni (ara sezzjoni 4.2).
English: The median tmax was 3.0 hours.
Maltese: It-tmax medjan kien 3.0 sigħat.
English: Oral administration of the capsule with an approximately 800 Kcal standard breakfast resulted in an up to 40 % increase in AUC of aprepitant.
Maltese: Amministrazzjoni orali tal-kapsula b'kolazzjon standard ta' madwar 800 Kcal irriżulta f'żieda ta' 40 % fl-AUC ta' aprepitant.
English: In a randomised, parallel, double-blind, active-controlled study, fosaprepitant 150 mg (N=1,147) was compared with a 3-day aprepitant regimen (N=1,175) in adult patients receiving a HEC regimen that included cisplatin (≥ 70 mg/m2).
Maltese: Fi studju randomised, paralell, double blind, ikkontrollat b'mod attiv, 150 mg ta' fosaprepitant (N=1,147) tqabbel mal-iskeda ta' għoti ta' aprepitant għal 3 ijiem (N=1,175) f'pazjenti adulti li kienu qed jirċievu skeda ta' għoti ta' HEC li kienet tinkludi cisplatin (≥ 70 mg/m2).
English: In a randomised, double-blind study in a total of 866 adult patients (864 females, 2 males) receiving chemotherapy that included cyclophosphamide 750-1,500 mg/m2; or cyclophosphamide
Maltese: Fi studju randomised, double blind, f'total ta' 866 pazjent adult (864 mara, 2 irġiel) li kienu qed jingħataw kimoterapija li kienet tinkludi cyclophosphamide 750-1500 mg/m2; jew cyclophosphamide
English: 25-120 hours
Maltese: 25-120 siegħa
English: Metabolism and nutrition disorders decreased appetite common polydipsia rare
Maltese: Disturbi fil-metaboliżmu u nnutrizzjoni tnaqqis fl-aptit komuni polidipsja rari
English: What EMEND contains - The active substance is aprepitant.
Maltese: X'fih EMEND - Is-sustanza attiva hi aprepitant.
English: For adolescents aged 12-17 years, EMEND is available as capsules containing 80 mg, or 125 mg of aprepitant.
Maltese: Għal adolexxenti ta' età minn 12-17-il sena, EMEND huwa disponibbli bħala kapsuli li fihom 80 mg, jew 125 mg ta' aprepitant.
English: For details on preparation and administration of the suspension, see section 6.6.
Maltese: Għal dettalji dwar il-preparazzjoni u l-għoti tas-suspensjoni, ara sezzjoni 6.6.
English: Hepatic impairment: Mild hepatic impairment (Child-Pugh class A) does not affect the pharmacokinetics of aprepitant to a clinically relevant extent.
Maltese: Indeboliment epatiku ħafif Child-Pugh klassi A) ma jaffettwax il farmakokinetika ta' aprepitant sa punt klinikament rilevanti.
English: Ondansetron 4 mg intravenously (N=526)
Maltese: 4 mg fil-vini (N=526)
English: A PET study in healthy young men administered a single oral dose of 165 mg aprepitant or a single intravenous dose of 150 mg fosaprepitant demonstrated similar brain NK1 receptor occupancy at Tmax, (≥ 99 %), 24 hours (≥ 99 %), 48 hours (≥ 97 %), and 120 hours (37 to 76 %) following dosing.
Maltese: Studju PET f'irġiel żgħażagħ f'saħħithom li ngħataw doża waħda ta' 165 mg ta' aprepitant mill-ħalq jew doża waħda ta' 150 mg ta' fosaprepitant minn ġol-vini wera okkupazzjoni tar-riċetturi NK1 filmoħħ fit-tmax, (≥ 99 %) tixxiebah, 24 siegħa (≥ 99 %), 48 siegħa (≥ 97 %), u 120 siegħa (37 sa 76 %) wara l-għoti tad-doża.
English: Inhibition of cytochrome P450 isoenzyme 3A4 (CYP3A4) by aprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious adverse reactions (see section 4.5).
Maltese: L-impediment ta' cytochrome P450 isoenżim 3A4 (CYP3A4) minħabba aprepitant jista' jirriżulta f'konċentrazzjonijiet ogħla fil-plażma ta' dawn issustanzi attivi, li potenzjalment jistgħu jikkawżaw reazzjonijiet avversi (ara sezzjoni 4.5).
English: 2-day treatment pack containing: 2 x 80 mg hard capsule 5 x 1 hard capsule
Maltese: U KONTENUT Kapsula iebsa waħda trattament ta' jumejn fih: 2 x 80 mg kapsula iebsa 5 x 1 kapsula iebsa
English: Based on interaction studies with tolbutamide and oral contraceptives, total exposure of concomitantly administered active substances metabolised by CYP2C9 or CYP3A4 may be reduced up to 15-30 %.
Maltese: Fuq il-bażi tal-istudji ta' interazzjoni ma' tolbutamide u kontraċettivi orali, l-esponiment totali ta' sustanzi attivi amministrati fl-istess ħin metabolizzati minn CYP2C9 jew CYP3A4 jista' jitnaqqas b'madwar 15-30 %.
English: Side effects for which the frequency is not known: - Stevens-Johnson syndrome/toxic epidermal necrolysis (rare severe skin reaction).
Maltese: - Sindrome ta' Stevens-Johnson/nekroliżi tossika tal-epidermide (reazzjoni qawwija rari fil ġilda).
English: After reconstitution, 1 mL oral suspension contains 25 mg of aprepitant - The other ingredients are: hydroxypropyl-cellulose (E 463), sodium laurilsulfate (E 487), sucrose and lactose (see section 2 under ‘EMEND contains sucrose and lactose'), red iron oxide (E 172) and sodium stearyl fumarate (E 485).
Maltese: Wara r-rikostituzzjoni, 1 mL ta' suspensjoni orali fih 25 mg ta' aprepitant - Is-sustanzi l-oħra huma: hydroxypropyl-cellulose (E 463), sodium laurilsulfate (E 487), sucrose u lactose (ara sezzjoni 2 taħt ‘EMEND fih sucrose u lactose'), iron oxide aħmar (E 172) u sodium stearyl fumarate (E 485).
English: Start of Therapy
Maltese: Bidu tat-Terapija
English: There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh class C).
Maltese: Ma hemm l-ebda data klinika jew farmakokinetika f'pazjenti b'indeboliment epatiku serju (Child-Pugh klassi C).
English: The 3-day oral aprepitant regimen resulted in an about 30-35 % reduction in AUC of CYP2C9 substrates and up to a 64 % decrease in ethinyl estradiol trough concentrations.
Maltese: L-iskeda ta' għoti ta' aprepitant mill-ħalq għal 3 ijiem wasslet għal tnaqqis ta' madwar 30-35 % fl-AUC ta' sustrati ta' CYP2C9 u tnaqqis sa 64 % fl-anqas konċentrazzjonijiet ta' ethinyl estradiol.
English: The powder for oral suspension contains sucrose and lactose.
Maltese: It-trab għal suspensjoni orali fih sucrose u lactose.
English: A single dose of aprepitant 200 mg on Day 1 co-administered with midazolam, a sensitive CYP3A4 substrate, on Days 1, 4 and 8 resulted in a 35 % reduction of midazolam AUC0-∞ on Day 8.
Maltese: Doża waħda ta' 200 mg ta' aprepitant f'Jum 1 mogħtija flimkien ma' midazolam, sustrat sensittiv ta' CYP3A4, fil-Jiem 1, 4 u 8 wassal għal tnaqqis ta' 35 % fl-AUC0-∞ ta' midazolam fil-Jum 8.
English: Each capsule contains 125 mg of sucrose (in the 125 mg capsule).
Maltese: Kull kapsula fiha 125 mg ta' sucrose (fil-kapsula ta' 125 mg).
English: Aprepitant is also an inducer of CYP2C9.
Maltese: Aprepitant jinduċi wkoll CYP2C9.
English: Each capsule contains 80 mg of sucrose (in the 80 mg capsule).
Maltese: Kull kapsula fiha 80 mg ta' sucrose (fil-kapsula ta' 80 mg).
English: Each sachet of EMEND for oral suspension contains 125 mg of aprepitant which is to be suspended in 4.6 mL of water giving a final concentration of 25 mg/mL.
Maltese: Kull qartas ta' EMEND għal suspensjoni orali fih 125 mg ta' aprepitant li għandu jitħallat ma' 4.6 mL ta' ilma biex tinkiseb konċentrazzjoni finali ta' 25 mg/mL.
English: EMEND 125 mg capsule
Maltese: EMEND 125 mg kapsuli iebsin.
English: Co-administration with warfarin (a CYP2C9 substrate) In patients on chronic warfarin therapy, the International Normalised Ratio (INR) should be monitored closely during treatment with EMEND and for 14 days following each 3-day course of EMEND (see section 4.5).
Maltese: Għoti flimkien ma' warfarin (substrat ta' CYP2C9) F'pazjenti fuq terapija kronika ta' warfarin, il-Proporzjon Normalizzat Internazzjonali (INRInternational Normalised Ratio) għandu jiġi ssorveljat b'attenzjoni waqt kura b'EMEND u għal 14-il jum wara kull kors ta' 3 ijiem ta' EMEND (ara sezzjoni 4.5).
English: In clinical interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron).
Maltese: Fi studji ta' interazzjonijiet kliniċi, aprepitant ma kellux effetti klinikament importanti fuq ilfarmakokinetiċi ta' ondansetron, granisetron, jew hydrodolasetron (il-metabolit attiv ta' dolasetron).
English: Control regimen n/m (%)
Maltese: Kors terapewtiku ta' trattament b'kontroll n/m (%)
English: After the treatment, EMEND causes a transient mild induction of CYP2C9, CYP3A4 and glucuronidation.
Maltese: Wara t-trattament, EMEND jikkawża induzzjoni ħafifa temporanja ta' CYP2C9, CYP3A4 u glukoronidazzjoni.
English: EMEND increased the AUC of midazolam 25 % on Day 4 and decreased the AUC of midazolam 19 % on Day 8 and 4 % on Day 15.
Maltese: EMEND żied l-AUC ta' midazolam b'25 % f'Jum 4 u naqqas l-AUC ta' midazolam b'19 % f'Jum 8 u b'4 % f'Jum 15.
English: 8 mg orally 8 mg orally 8 mg orally
Maltese: 8 mg mill-ħalq 8 mg mill ħalq
English: * - Overall phase
Maltese: Globalment§
English: The terminal half-life ranged from approximately 9 to 13 hours.
Maltese: Il-half-life terminali kienet bejn 9 u 13-il siegħa, bejn wieħed u ieħor.
English: In a second multicentre, randomised, double-blind, parallel-group, clinical study, the aprepitant regimen was compared with standard therapy in 848 adult patients (652 females, 196 males) receiving a chemotherapy regimen that included any intravenous dose of oxaliplatin, carboplatin, epirubicin, idarubicin, ifosfamide, irinotecan, daunorubicin, doxorubicin; cyclophosphamide intravenously (< 1,500 mg/m2); or cytarabine intravenously (> 1 g/m2).
Maltese: Fit-tieni studju kliniku, multiċentriku, randomised, double-blind, fi gruppi paralleli, ir-reġimen ta' aprepitant tqabbel ma' kura standard f'848 pazjent adult (652 mara, 196 raġel) li kienu qed jingħataw reġimen ta' kimoterapija li kien jinkludi kwalunkwe doża għal ġol-vini ta' oxaliplatin, carboplatin, epirubicin, idarubicin, ifosfamide, irinotecan, daunorubicin, doxorubicin; cyclophosphamide għal ġolvini (< 1,500 mg/m2); jew cytarabine għal ġol-vini (> 1 g/m2).
English: Conclusions regarding the influence of moderate hepatic impairment (Child-Pugh class B) on aprepitant pharmacokinetics cannot be drawn from available data.
Maltese: Ma jistgħux isiru konklużjonijiet dwar linfluwenza ta' indeboliment epatiku moderat (Child-Pugh klassi B) fuq il-farmakokinetiċi ta' aprepitant mid-data disponibbli.
English: In clinical interaction studies, aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg on Days 2 and 3, did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron).
Maltese: Fi studji ta' interazzjoni klinika, aprepitant, meta ngħata bi skeda ta' 125 mg fil-Jum 1 u 80 mg filJiem 2 u 3, ma kellux effetti importanti b'mod kliniku fuq il-farmakokinetika ta' ondansetron, granisetron, jew hydrodolasetron (il-metabolit attiv ta' dolasetron).
English: This combination (i.e. EMEND, ondansetron and dexamethasone) decreased the AUC of oral midazolam 16 % on Day 6, 9 % on Day 8, 7 % on Day 15 and 17 % on Day 22.
Maltese: Din it-taħlita (jiġifieri EMEND, ondansetron u dexamethasone) naqqset l-AUC ta' midazolam mill-ħalq b'16 % f'Jum 6, b'9 % f'Jum 8, b'7 % f'Jum 15 u bi 17 % f'Jum 22.
English: Aprepitant regimen (N= 521)
Maltese: Aprepitant (N= 521) †
English: Aprepitant is a substrate, a moderate inhibitor, and an inducer of CYP3A4.
Maltese: Aprepitant huwa sustrat, inibitur moderat, u induttur ta' CYP3A4.
English: EMEND contains the active substance ‘aprepitant.'
Maltese: X'fih EMEND Is-sustanza attiva hi aprepitant.
English: - with medicines containing pimozide (used to treat psychiatric illnesses), terfenadine and astemizole (used for hay fever and other allergic conditions), cisapride (used for treating digestive problems).
Maltese: - ma' mediċini li fihom pimozide (użati għat-trattament ta' mard psikjattriku), terfenadine u astemizole (użati għal hay fever u kundizzjonijiet allerġiċi oħra), cisapride (użat għat-trattament ta' problemi diġestivi).
English: Excipients with known effect Each sachet contains approximately 125 mg of sucrose and 468.7 mg lactose (as anhydrous).
Maltese: Kull qartas fih madwar 125 mg ta' sucrose u 468.7 mg lactose (bħala anidru).
English: The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolised via CYP3A4 (alprazolam, triazolam) should be considered when co-administering these medicinal products with EMEND (125 mg/80 mg).
Maltese: L-effetti potenzjali ta' żidiet fil-konċentrazzjonijiet ta' midazolam fil-plażma jew benzodiazepines oħra metabolizzati permezz ta' CYP3A4 (alprazolam, triazolam) għandhom jiġu kkunsiderati meta dawn il-prodotti mediċinali jingħataw flimkien ma' EMEND (125 mg/80 mg).
English: • Use the 5 mL oral dispenser to measure 4.6 mL of water, which is added into the mixing cup.
Maltese: • Uża d-dipsenser orali ta' 5 mL biex tkejjel 4.6 mL ta' ilma, li għandhom jitpoġġew fit-tazza li tħallat fiha.
English: During treatment with EMEND, CYP3A4 is inhibited.
Maltese: Matul trattament b'EMEND, CYP3A4 huwa inibit.
English: Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1.
Maltese: Dexamethasone għandu jingħata 30 minuta qabel it-trattament ta' kimoterapija fl-1 Jum.
English: - The other ingredients are: sucrose, microcrystalline cellulose (E 460), hydroxypropylcellulose (E 463), sodium laurilsulfate, gelatin, titanium dioxide (E 171), shellac, potassium hydroxide, and black iron oxide (E 172); the 125 mg hard capsule also contains red iron oxide (E 172) and yellow iron oxide (E 172).
Maltese: - Is-sustanzi l-oħra huma: sukrożju, microcrystalline cellulose (E 460), hydroxypropylcellulose (E 463), sodium laurilsulfate, gelatin, titanium dioxide (E 171), xellak, potassium hydroxide u black iron oxide (E 172); il-kapsula iebsa ta' 125 mg fiha wkoll red iron oxide (E 172) u yellow iron oxide (E 172).
English: What EMEND is and what it is used for
Maltese: L-iskeda ta' għoti ta' ta'
English: The other ingredients are: sucrose, microcrystalline cellulose (E 460), hydroxypropylcellulose (E 463), sodium laurilsulfate, gelatin, titanium dioxide (E 171), Indigo carmine (E 132), shellac, potassium hydroxide, and black iron oxide (E 172).
Maltese: Is-sustanzi l-oħra huma: sucrose, microcrystalline cellulose (E 460), hydroxypropylcellulose (E 463), sodium laurilsulfate, gelatin, titanium dioxide (E 171), Indigo carmine (E 132), shellac, potassium hydroxide, u iron oxide iswed (E 172).
English: Aprepitant regimen n/m (%)
Maltese: Kors terapewtiku ta' trattament b'aprepitant n/m (%)
English: PC:
Maltese: KIF:
English: Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other active substances that are known to be metabolised by CYP2C9 are administered with EMEND 165 mg.
Maltese: Hija rrikmandata l-kawtela meta warfarin, acenocoumarol, tolbutamide, phenytoin jew sustanzi attivi oħra li huma magħrufa li huma mmetabolizzati permezz ta' CYP2C9 jingħataw ma' 165 mg ta' EMEND.
English: EMEND 125 mg and 80 mg hard capsules are supplied in the following pack sizes: - Aluminium blister containing one 80 mg capsule - 2-day treatment pack containing two 80 mg capsules - 5 Aluminium blisters each containing one 80 mg capsule - Aluminium blister containing one 125 mg capsule - 5 Aluminium blisters each containing one 125 mg capsule - 3-day treatment pack containing one 125 mg capsule and two 80 mg capsules
Maltese: - Folja tal-Aluminju li jkun fiha kapsula waħda ta' 80 mg - Pakkett ta' trattament ta' jumejn li jkun fih żewġ kapsuli ta' 80 mg - 5 folji tal-Aluminju li kull waħda jkun fiha kapsula waħda ta' 80 mg - Folja tal-Aluminju li jkun fiha kapsula waħda ta' 125 mg - 5 folji tal-Aluminju li kull waħda jkun fiha kapsula waħda ta' 125 mg - Pakkett ta' trattament ta' tlett ijiem li fih kapsula waħda ta' 125 mg u żewġ kapsuli ta' 80 mg
English: During treatment for chemotherapy induced nausea and vomiting (CINV), the 3-day 125 mg/80 mg regimen of aprepitant is a moderate inhibitor of CYP3A4.
Maltese: Waqt trattament għan-nawseja u rimettar ikkaġunati mill-kimoterapija (CINV), il-kors ta' 125 mg/80 mg ta' apretitant għal 3 ijiem huwa inibitur moderat ta' CYP3A4.
English: WHEN:
Maltese: META:
English: Occupancy of brain NK1 receptors by aprepitant correlate well with aprepitant plasma concentrations.
Maltese: L-okkupazzjoni tar-riċetturi NK1 tal-moħħ minn aprepitant ikkorrelata tajjeb mal-konċentrazzjonijiet ta' aprepitant fil-plasma.
English: Hydroxypropylcellulose (E 463) Sodium laurilsulfate (E 487) Sucrose
Maltese: FARMAĊEWTIKU 6.1 Lista ta' eċċipjenti Hydroxypropylcellulose (E 463) Sodium laurilsulfate (E 487)
English: EMEND capsules contain sucrose.
Maltese: Il-kapsuli EMEND fihom is-sucrose.